Résumé :
|
[BDSP. Notice produite par INIST-CNRS lCR0x9I8. Diffusion soumise à autorisation]. Experimental evidence and case-control studies suggest that dihydropyridine calcium channel blockers (DiCCBs) may protect against Parkinson's disease. The authors conducted a historical cohort study in Denmark to investigate the association between DiCCB use and risk of Parkinson's disease (1998-2006). Individual-level data on filled drug prescriptions, diagnostic information, and covariates were linked between nationwide registries. Among DiCCB users, 173 incident cases of Parkinson's disease were detected during 461,984 person-years of follow-up, compared with 5,538 cases during 17,343,641 person-years of follow-up among nonusers. After adjustment for age, sex, year, propensity score, and use of other antihypertensive drugs and statins, DiCCB use was associated with a reduced risk of Parkinson's disease (rate ratio (RR)=0.71,95% confidence interval (CI) : 0.60,0.82). This association was not present in patients who had previously used DiCCBs (RR=1.04,95% CI : 0.87,1.24). DiCCB users aged>=65 years were at lower risk of Parkinson's disease than DiCCB users aged<65 years (RR=0.59,95% CI : 0.40,0.85). Among patients with Parkinson's disease, DiCCB use was associated with reduced risk of death (adjusted RR=0.66,95% CI : 0.47,0.91) but not dementia (adjusted RR=0.97,95% CI : 0.60,1.56). In conclusion, DiCCB exposure was associated with a reduced risk of incident Parkinson's disease, particularly in older patients, and with reduced mortality among patients with Parkinson's disease.
|